Donna L. Mendrick
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Human Genome Sciences (United States) (1996–2000); GenVec (1999–2008); University of North Carolina at Chapel Hill (2015); Brigham and Women's Hospital (1986–2015); Center for Food Safety and Applied Nutrition (2024); Environmental Protection Agency (2024); United States Food and Drug Administration (2009–2025); Center for Drug Evaluation and Research (2024); Harvard University (1986–2015); Howard University (2024); University of Georgia (2024); University of California, San Francisco (1996); University of Milan (2024); National Institute of Environmental Health Sciences (2015); Ecogenomics (Japan) (2006–2008); Dana-Farber Cancer Institute (1986); Charles River Laboratories (United States) (2024); Applied Logic Laboratory (Hungary) (2003); DK4 (1993); Food and Drug Administration (2010–2024); Dana-Farber Brigham Cancer Center (1986); InnoGenomics (United States) (2004); University at Buffalo, State University of New York (1980–1981); Mississippi State University (2024)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Donna L. Mendrick's research focuses on the development and implementation of new approach methodologies (NAMs) in toxicity testing, aiming to reduce reliance on animal models. Her work investigates the potential value of microphysiological systems (MPS), also known as organ-on-a-chip technology, for studying drug-induced liver injury and for broader applications in protecting human and animal health.
Mendrick has published on the challenges and considerations for adopting NAMs in pharmaceutical development from an FDA/CDER perspective. She also examines the progress of U.S. federal agencies in implementing alternative testing methods. Her research group explores biology-inspired dynamic microphysiological systems to revolutionize basic research, healthcare, and animal welfare, with recent work also considering animal MPS and the 3Rs (Replacement, Reduction, Refinement) in drug development.
Metrics
- h-index: 41
- Publications: 101
- Citations: 9,062
Selected Publications
-
Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development (2025)
-
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare (2025)
-
Potential value of animal microphysiological systems (2024)
-
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods (2024)
-
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies (2023)
-
Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury (2022)
-
The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps (2020)
-
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs) (2020)
-
“Natural” is not synonymous with “Safe”: Toxicity of natural products alone and in combination with pharmaceutical agents (2020)
-
A hybrid gene selection approach to create the S1500+ targeted gene sets for use in high-throughput transcriptomics (2018)
-
Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic (2017)
-
Proteomic analysis of acetaminophen-induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury (2016)
-
sNebula, a network-based algorithm to predict binding between human leukocyte antigens and peptides (2016)
-
The Next Generation of Risk Assessment Multi-Year Study—Highlights of Findings, Applications to Risk Assessment, and Future Directions (2016)
-
Adverse outcome pathways: From research to regulation scientific workshop report (2016)
Collaboration Network
Top Collaborators
- Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
- Potential value of animal microphysiological systems
- Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development
- Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods
- Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare
- Potential value of animal microphysiological systems
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare
- Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
- Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development
- Potential value of animal microphysiological systems
- Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
Similar Researchers
Based on overlapping research topics